ClinicalTrials.gg
TerminatedNCT01707680NICEWEANUpdated Sep 6, 2019

Non-interventional Comparison of Sedatives on Weaning From Mechanical Ventilation in Intensive Care Patients

An observational study in Critical Illness, sponsored by Orion Corporation, Orion Pharma. Terminated at 3 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-06.

Sponsored by Orion Corporation, Orion Pharma · Observational

How we know

Why this study was terminated
Halted due to slow recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
155
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine whether the use of different sedatives affect the weaning process from mechanical ventilation in intensive care patients.

Read the detailed description

Traditionally patients with ongoing mechanical ventilation have been sedated to assure absence of pain, anxiety and to provide comfort. Unfortunately this approach might have negative consequences such as prolonged time for mechanical ventilation, length of stay in the ICU and hospital.

In this study, the investigators would like to investigate (in an exploratory way due to the non-interventional setup) whether weaning from mechanical ventilation will be affected by the choice of sedatives - including dexmedetomidine, midazolam and propofol. This study also aims at investigating how the choice of primary sedative will affect delirium/anxiety, need of other medications (sedatives, analgesics, anti-psychotics), quality of life after ICU and the presence of Post-Traumatic Stress Disorder. In addition, the investigators aim at receiving information from the caregivers on their ICU experience, as recent data imply that not only the ICU patient but also the caregiver suffer from PTSD after the ICU stay.

02

Conditions studied

  • Critical Illness

Browse trials for

Keywords

  • weaning
  • mechanical ventilation
  • dexmedetomidine
  • propofol
  • midazolam
03

In context

Critical Illness

1,787 studies on the registry are indexed under Critical Illness; 445 are open to participants now.

This study's enrollment of 155 is above the median of 140 across 816 observational studies indexed under Critical Illness.

Browse Critical Illness studies →

Lead sponsor

Orion Corporation, Orion Pharma is the lead sponsor of 101 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult general intensive care patients Need of mechanical ventilation >24 hours Need of light to moderate sedation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Admitted to a general ICU ward
  • ≥ 18years
  • Intubated and mechanically ventilated for at least 24 hours
  • Need of light to moderate sedation (corresponding to RASS 0 - (-3) or MAAS 2-3)
  • Sedated with dexmedetomidine, midazolam and/or propofol
  • Good knowledge in Swedish language
  • Signed

Exclusion criteria

Exclusion criteria:

  • Lack of fulfilling prescribed sedation regime
  • Estimated high risk of death during the study period, according to investigator (roughly equal to estimated mortality rate (EMR) > 80% )
  • Tracheotomy
  • Change in sedative drugs since the "fit for weaning" time point
  • Use of other alpha-2 agonists (clonidine) during ICU stay
  • Positive pregnancy test or currently lactating/ known pregnancy or lactation
  • Participation in other study involving use of a pharmacologically active compound
  • Patients with limitations in therapy
  • Otherwise unable to fulfill the study, according to investigator's opinion
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
155 participants (actual)
Patient registry
No

Groups and cohorts

  • Dexmedetomidine

    Here, patients to be included are those being sedated with dexmedetomidine as primary sedative.

    Other: SOC

  • Propofol

    Here, patients to be included are those being sedated with propofol as primary sedative.

    Other: SOC

  • Midazolam

    Here, patients to be included are those being sedated with midazolam as primary sedative

    Other: SOC

Interventions

  • OtherSOC

    Patient are given standard of care

06

What researchers measure

Primary outcomes

  1. The time point from when the patient is considered "fit for weaning" to the actual time point for extubation

    Time frame: 30 days

Secondary outcomes

  1. Time-point for patient being considered "fit for extubation"

    Time frame: 30 days

  2. Total time in mechanical ventilation

    Time frame: 30 days

  3. Extubation failure (re-intubation within 24 hours)

    Time frame: 24 hours

  4. Anxiety/delirium assessments

    RASS/MAAS sedation scales and ICDSC/CAM-ICU delirium assessments methods are used, as appropriate

    Time frame: 30 days

  5. Length of ICU stay (actual time of discharge)

    Time frame: 30 days

  6. QoL (15D)

    Time frame: 2-4 months post-ICU discharge

  7. Post-Traumatic Stress Disorder assessment - PTSS14 questionnaire

    This assessment will be offered to the ICU patients but also to their caregivers.

    Time frame: 2-4 months post-ICU discharge

  8. Total duration of sedation

    Time frame: 30 days

  9. Number of days using opioids

    Time frame: 30 days

  10. Number of days using antipsychotic/neuroleptic drugs

    Time frame: 30 days

07

Study locations

3 sites
  • Danderyds Hospital Anestesi- och intensivvårdskliniken
    Danderyd, SE18288, Sweden
  • Capio S:t Goran Hospital, Anestesikliniken
    Stockholm, SE11281, Sweden
  • Örebro University Hospital, Anestesi- och intensivvårdskliniken
    Örebro, SE70185, Sweden
08

References and documents

Publications

  • Nunes SL, Forsberg S, Blomqvist H, Berggren L, Sorberg M, Sarapohja T, Wickerts CJ. Effect of Sedation Regimen on Weaning from Mechanical Ventilation in the Intensive Care Unit. Clin Drug Investig. 2018 Jun;38(6):535-543. doi: 10.1007/s40261-018-0636-2. PubMed 29502195 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2012 to primary completion in Nov 2015, 41 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2012
First posted
Oct 16, 2012
StartActual
Jun 1, 2012
Primary completionActual
Nov 1, 2015
CompletionActual
Nov 1, 2015
Last update
Sep 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01707680
Responsible party
Sponsor
First posted
Oct 16, 2012
Start date
Jun 1, 2012
Primary completion
Nov 1, 2015
Completion
Nov 1, 2015
Last update
Sep 6, 2019

Study contacts

Carl-Johan Wickerts, MD
principal investigator · Danderyds Hospital, Danderyd, Sweden

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion